Available Technologies
# of Displayed Technologies: 10 / 10
Applied Category Filter (Click To Remove): Oncology
Addressing the Challenges in HCC Treatment with Innovative Technology
TS-062690 — Novel niclosamide analogues with improved bioavailability and mitigated dose-limiting toxicities.
Hepatocellular carcinoma (HCC) poses a significant global health challenge, being a predominant form of liver cancer with high mortality rates. The disease exhibits sexual dimorphism, disproportionately affecting males.
The Need
Despite the crucial role of androgen receptors (AR) in HCC progress…
- College: College of Pharmacy
- Inventors: Coss, Christopher; Cheng, Jeffrey; Cheng, Xiaolin; Kulp, Samuel; Li, Tom; Montgomery, Emma; Xing, Enming
- Licensing Officer: Willson, Christopher
Transducin β-like protein 1 X-Linked Selective Degraders as Anti-cancer Therapeutics
TS-062685 — Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. The most common cancers are breast, lung, colon and rectum and prostate cancers.
The Need
Current cancer treatments mainly rely on chemotherapy, radiation, surgery and bon…
- College: College of Pharmacy
- Inventors: Cheng, Xiaolin; Alinari, Lapo; Li, Pui-Kai "Tom"; Yang, Rui
- Licensing Officer: Willson, Christopher
Dual Androgen Receptor/AKR1C3 Inhibitors for Prostate Cancer
TS-062605 — The Need:
Castration-resistant prostate cancer (CRPC) poses a significant challenge in oncology, with existing therapies often leading to resistance and disease progression. Key drivers of resistance include the androgen receptor (AR) and aldo-keto reductase family 1 member C3 (AKR1C3). Novel treat…
- College: College of Pharmacy
- Inventors: Li, Pui-Kai "Tom"; Cheng, Xiaolin; Kong, Xiaotian; Xing, Enming
- Licensing Officer: Schworer, Adam
Automated Detection of Tumor Budding in Colorectal Cancer
TS-039267 — A non-invasive and automated tumor budding image analysis system for colorectal cancer. This program can detect tumor buds in traditional H&E stained sections without the need for manual assessment.
Colorectal cancer is the third most commonly diagnosed cancer in the United States. With a survival rate of less than 65%, early detection and treatment are key factors in survival. Tumor budding, associated with higher tumor stage, lymph node metastasis, and decreased disease-free survival, has e…
- College: College of Medicine (COM)
- Inventors: Gurcan, Metin; Ahmad Fauzi, Mohammad Faizal; Chen, Wei "Wei"; Frankel, Wendy
- Licensing Officer: Hampton, Andrew
Treatment of Multiple Sclerosis with Small Molecule IL-6/STAT3 Inhibitors
TS-038701 —
Small-molecule prodrugs that target IL-6/STAT3 signaling pathway.
Multiple Sclerosis (MS), an unpredictable and disabling autoimmune disease affecting the central nervous system, is the leading cause of non-traumatic neurological disability in young adults. There have been important advances in MS therapy, such as drugs that slow the progression of the disease a…
- College: College of Medicine (COM)
- Inventors: Yang, Yuhong; Li, Chenglong; Racke, Michael
- Licensing Officer: He, Panqing
Novel Small-Molecule Integrin-linked Kinase/Phosphoinositide-dependent Protein Kinase-2 Inhibitors
TS-037647 — A novel set of molecules that inhibit integrin-linked kinase in order to suppress tumor cell growth and metastasis.
The Akt signaling pathway is responsible for apoptosis, cell proliferation, and metabolism. In tumor cells, this pathway is up-regulated and aids in promoting cancer cell survival. Complete activation of Akt pathway requires phosphorylation at two amino-acid residues, which are phosporylated by se…
- College: College of Pharmacy
- Inventors: Chen, Ching-Shih; Kulp, Samuel; Lee, Su-Lin
- Licensing Officer: Taysavang, Panya
Small Molecule AR-Ablative Agents
TS-014842 — A new strategy for using androgen receptor ablative agents has been developed for prostate cancer therapy.
Hormone-refractory prostate cancer is incurable, and patients with this disease have few treatment options. Dysregulation of the androgen receptor (AR) is a hallmark of this incurable cancer. Molecular changes during cancer enhance AR sensitivity or permit AR activation by antiestrogen so that pro…
- College: College of Pharmacy
- Inventors: Chen, Ching-Shih; Wang, Dasheng; Yang, Jian
- Licensing Officer: Taysavang, Panya
Novel Indole-3-Carbinol-Derived Antitumor Agents
TS-014815 — An anti-tumor agent developed from indol-3-carbinol, a naturally occurring phytochemical in cruciferous vegetables.
According to the Center for Disease Control and Prevention, cancer is the second leading cause of death in the US at approximately 600,000 deaths per year. In addition, the National Cancer Institute estimates that nearly 1.7 million cases of cancer are diagnosed each year. A report from U.S. News …
- College: College of Pharmacy
- Inventors: Chen, Ching-Shih; Weng, Jing-ru
- Licensing Officer: Taysavang, Panya
Novel Protein Kinase C Delta Activators
TS-014754 — A novel anti-cancer agent (OSU-2S) that is devoid of S1P1 receptor activity and is highly effective in suppressing hepatocellular carcinoma tumor growth in vivo.
The third leading cause of cancer death worldwide is hepatocellular carcinoma (HCC). Due to the rise in the incidence of hepatitis C virus infection, HCC is expected to increase in the United States. Many patients with HCC are not candidates for surgery because of the location or size of their tum…
- College: College of Pharmacy
- Inventors: Chen, Ching-Shih; Byrd, John; Kulp, Samuel; Muthusamy, Natarajan; Wang, Dasheng
- Licensing Officer: Taysavang, Panya
Glucose Transporter Inhibitors (GLUT1 Inhibitors)
TS-014734 — A potential cancer treatment that suppresses the ability for cancer cells to intake glucose, thereby hampering cancer cell production.
A fundamental property of neoplastic cells is the shift in cellular metabolism from oxidative phosphorylation to aerobic glycolysis. This glycolytic shift, called the Warburg effect, enables cancer cells to adapt to low-oxygen microenvironments, to generate biosynthetic building blocks for cell pr…
- College: College of Pharmacy
- Inventors: Chen, Ching-Shih; Kulp, Samuel; Wang, Dasheng
- Licensing Officer: Taysavang, Panya
